<DOC>
	<DOCNO>NCT02800070</DOCNO>
	<brief_summary>This first-in-human study treatment Fabry disease . Eligible patient autologous stem cell transplantation use CD34+ cell transduce lentivirus vector contain human alpha-gal A gene . The researcher study would like see re-introduction transduced cell help increase level alpha-gal A enzyme level determine safety toxicity autologous stem cell transplantation use CD34+ cell transduce lentivirus vector contain alpha-gal A gene . This study 's objective determine safety toxicity lentivirus alpha-gal A transduce CD34+ cell adult male Fabry disease .</brief_summary>
	<brief_title>Autologous Stem Cell Transplantation Cells Engineered Express Alpha-Galactosidase A Patients With Fabry Disease</brief_title>
	<detailed_description />
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>1 . Male patient 1850 year age time enrollment 2 . Diagnosis Fabry disease ( FD ) define low absent Î±gal A activity 3 . Classic FD Type I phenotype alphagalactosidase A ( GLA ) genotyping 4 . Patients enzyme replacement therapy ( ERT ) prior enrollment 5 . Eastern Cooperative Oncology Group ( ECOG ) Performance status 0 1 6 . Adequate organ function within 21 day prior PreTreatment Phase : 7 . Willing capable sign give write informed consent accordance Research Ethics Board ( REB ) requirement 8 . Willing comply procedure outline study protocol , cooperative protocol schedule , able return safety evaluation , otherwise likely complete study 9 . Willing abstain sexual activity willing use condom sexual intercourse day Melphalan administration day 1 Phase 3 12 month followup posttransplant . 10 . Willing donate sperm receive Melphalan . Sperm banking recommend patient would like father child future . 1 . Males variant Fabry Disease . 2 . Female gender 3 . Use immunosuppressive agent anticoagulant 4 . Ongoing ERTrelated infusion associate reaction moderatetosevere intensity 5 . Presence antiagalsidase immunoglobulin ( Ig ) G antibody threshold ( 5fold normal ; ) evidence high titre neutralize antibody 6 . Blood test positive Hepatitis B virus ( HBV ) , Hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) , human Tcell lymphotropic virus type 1 ( HTLV1 ) , human Tcell lymphotropic virus type 1 ( HTLV2 ) , Venereal Disease Research Laboratory test ( VDRL ; Transmissible Disease ( TD ) test do PreTreatment Phase 2 see section 5.1 full panel TD test . Patients exclude study positive TD test list exclusion ) . 7 . Uncontrolled bacterial , viral , fungal infection 8 . Prior malignancy except resect basal cell carcinoma 9 . Chronic Kidney Disease ( CKD ) stage &gt; 2 10 . History heart failure leave ventricle ejection fraction ( LVEF ) &lt; 45 % moderate severe diastolic dysfunction standard criterion 11 . Arrhythmia : bundle branch block , heart block degree II III , atrial fibrillation , supraventricular tachycardia , ventricular tachycardia , ventricular fibrillation , cardiac arrest , pacemaker , implantable cardiac defibrillator 12 . Coronary artery disease angina , prior myocardial infarction , percutaneous transluminal coronary angioplasty without stent , coronary artery bypass graft surgery , moderate severe valvular heart disease , valve replacement surgery 13 . Uncontrolled hypertension 14 . Diabetes mellitus 15 . Advanced liver disease , liver failure , cirrhosis 16 . Immune deficiency state 17 . Moderatetosevere chronic obstructive pulmonary disease ( COPD ) 18 . Any hematological condition white blood cell ( WBC ) &lt; 3.0 x109/L , platelet count &lt; 100 x109/L , and/or hemoglobin &lt; 100 g/L 19 . Prior bone marrow transplant ( BMT ) organ transplant 20 . Any condition would preclude use Melphalan 21 . Use drug cytotoxic immunosuppressive effect within 60 day trial entry 22 . Uncontrolled psychiatric disorder 23 . Active chronic infection 24 . Prior tuberculosis 25 . Any serious concurrent disease 26 . Cognitive impairment would prevent informed consent 27 . Use investigational drug within 30 day stem cell transplant ( SCT )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>autologous stem cell transplant</keyword>
	<keyword>gene therapy</keyword>
	<keyword>Fabry disease</keyword>
	<keyword>lentivirus</keyword>
	<keyword>haematopoietic stem cell transplant</keyword>
</DOC>